Clinical Trial Update: A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial evaluating the combination of tamoxifen and LY2228820 in advanced or metastatic breast cancer that progressed on aromatase inhibitor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• LY2228820 (LY2228820)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: Postmenopausal, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED